藥明生物(02269.HK)新加坡CRDMO中心模塊化生物製劑廠房啟動建設
藥明生物(02269.HK)宣布,旗下位於新加坡CRDMO中心的模塊化生物製劑廠房近日正式啟動建設,項目建成後總建築面積達約3萬平方米,預料將成為全球規模最大的模塊化生物製劑生產設施之一,預計於2027年正式投入營運。
該廠房將配備先進的生產線,包括配備3條預充針(PFS)生產線和2條西林瓶液體和凍乾粉針生產線,並設有支持全面放行和穩定性測試的質量控制中心實驗室,以及生產科技與技術實驗室,預期可顯著提升端到端的製劑服務能力。
早前藥明生物與森松法瑪度(Pharmadule Morimatsu)達成戰略合作,目前470個主體模塊正在森松法瑪度常熟工廠內生產,未來將運往新加坡大士生物醫藥園進行安裝。另外,藥明生物新加坡CRDMO中心的模塊化原液(DS)廠房已處於設計階段。
藥明生物首席執行官陳智勝表示,通過與森松法瑪度合作,應用模塊化解決方案推進新加坡CRDMO中心生物製劑廠房建設,可加快項目進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.